MEDICAL SERIES- PART I – ARTIFICIAL INTELLIGENCE & PARKINSON

We invite you to discover the work of researchers in the field of Parkinson's disease. We welcome Madeleine SHARP, Doctor of Neurology, and Tristan GLATARD, Professor of Artificial Intelligence, who are working together to predict disease progression, characterize subtypes and much more.

These two researchers will explain the clinical issues at stake, and the Artificial Intelligence models associated with them. A look into the medicine of the future!

With the financial participation of the Government of Quebec as part of the Quebec ami des ainés program

FRENCH TRANSLATED TO ENGLISH SIMULTANEOUSLY

BIOs

TRISTAN GLATARD

Tristan Glatard is a Senior Professor in Computer Science and Software Engineering at Concordia University, Canada Research Chair (Tier II) on Big Data Infrastructures for Neuroinformatics, and co-Director of the Concordia Applied Artificial Intelligence Institute. He leads a research group of 10 graduate students and post-docs that aims at designing Big Data infrastructures to enable efficient, open and reproducible brain image analysis. He obtained a PhD in 2007 from Université de Nice Sophia-Antipolis, and then developed a research program on scientific computing and medical imaging as a post-doctoral researcher at the University of Amsterdam (2007-2008), research scientist at Centre National de la Recherche Scientifique in France (2008-2016), and Visiting Scholar at McGill University (2013-2016).

MADELEINE SHARP

Dr. Madeleine Sharp is a neurologist specializing in movement disorders. Her research focuses on understanding the cognitive mechanisms underlying cognitive dysfunction in patients with movement disorders. Movement disorders that affect the basal ganglia, such as Parkinson's disease and Huntington's disease, are increasingly recognized as impairing much more than movement. Cognitive and behavioral symptoms are very common in these patients, but remain poorly understood and difficult to treat. His research combines behavioral experiments, pharmacological manipulations and neuroimaging in patients and healthy populations. Ultimately, the aim is to develop more precise models of cognitive dysfunction in patients, based on neurobiology, in order to develop and reliably test new behavioral and pharmacological therapies.